Cargando…

bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer.

Seventy-seven men with histologically proven and newly diagnosed prostate cancer we investigated for the presence of bcl-2 protein overexpression and p53 protein accumulation 1 immunohistochemistry. Forty-five men had evidence of locally advanced and metastatic disease and we treated by means of hor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Apakama, I., Robinson, M. C., Walter, N. M., Charlton, R. G., Royds, J. A., Fuller, C. E., Neal, D. E., Hamdy, F. C.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075934/ https://www.ncbi.nlm.nih.gov/pubmed/8883414

Ejemplares similares

Pathogenesis of prostate cancer and hormone refractory prostate cancer
por: Girling, J. S., et al.
Publicado: (2007)

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
por: Abdel-Fattah, R., et al.
Publicado: (1998)

Leptomeningeal Metastases in Hormone Refractory Prostate Cancer
por: Ng, Jessica Y, et al.
Publicado: (2018)

Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma
por: Wobser, M, et al.
Publicado: (2007)

Neural network analysis of combined conventional and experimental prognostic markers in prostate cancer: a pilot study.
por: Naguib, R. N., et al.
Publicado: (1998)

Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine.
por: de Souza, P. L., et al.
Publicado: (1997)

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007)

Update in palliative management of hormone refractory cancer of prostate
por: Singh, Pratipal, et al.
Publicado: (2007)

Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases
por: Lam, Marnix G. E. H., et al.
Publicado: (2008)

Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis
por: Bruchmann, Anja, et al.
Publicado: (2013)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Sinibaldi, Victoria J
Publicado: (2007)

Hormone refractory prostate cancer: Current understanding and future perspectives
por: Khochikar, Makarand
Publicado: (2007)

TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer
por: Kumar, Gautam
Publicado: (2020)

Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity
por: Wei, Hudie, et al.
Publicado: (2023)

p53 nuclear accumulation as an early indicator of lethal prostate cancer
por: Quinn, David I., et al.
Publicado: (2019)

p53 protein overexpression and allele loss of p53 gene in gastric adenocarcinoma.
por: Choi, S. W., et al.
Publicado: (1994)

Δ122p53, a mouse model of Δ133p53α, enhances the tumor-suppressor activities of an attenuated p53 mutant
por: Slatter, T L, et al.
Publicado: (2015)

Primary prostate sarcoma: how to manage following diagnosis at transurethral resection
por: Hicks, Natalie, et al.
Publicado: (2016)

Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer
por: Birtle, A J, et al.
Publicado: (2004)

Bcl11a is essential for lymphoid development and negatively regulates p53
por: Yu, Yong, et al.
Publicado: (2012)

Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline
por: Yates, C, et al.
Publicado: (2005)

Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells
por: Tsakalozou, Eleftheria, et al.
Publicado: (2012)

Phosphorylation of the Androgen Receptor by PIM1 in Hormone Refractory Prostate Cancer
por: Ha, Susan, et al.
Publicado: (2012)

Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion
por: Conrad, Fraser, et al.
Publicado: (2009)

Ocular Fireworks Injuries in Eastern Nigeria: A 3-Year Review
por: Apakama, Akunne Ijeoma, et al.
Publicado: (2019)

Overexpression of p53 protein during pancreatitis.
por: Maacke, H., et al.
Publicado: (1997)

Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas.
por: Watson, A. J., et al.
Publicado: (1996)

Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer
por: Tam, L, et al.
Publicado: (2007)

Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia.
por: Kühl, J. S., et al.
Publicado: (1997)

Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease
por: Berruti, A, et al.
Publicado: (2005)

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
por: Collins, R, et al.
Publicado: (2006)

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
por: Edwards, J, et al.
Publicado: (2003)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
por: Calcagno, Fabien, et al.
Publicado: (2012)

EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment
por: Guérin, Olivier, et al.
Publicado: (2010)

Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer
por: Hu, Meichun, et al.
Publicado: (2015)

Overexpression of MDM2 in MCF‐7 Promotes Both Growth Advantage and p53 Accumulation in Response to Estradiol
por: Saji, Shigehira, et al.
Publicado: (1999)

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011)

Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment
por: Neely, Victoria, et al.
Publicado: (2023)

Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer.
por: Kaklamanis, L., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_i3o026b6t7cb1j68k661esncac